Education
About Us
Working with TipRanks
Follow Us
Island Pharmaceuticals Ltd (AU:ILA)
ASX:ILA
RESEARCH TOOLSreports
ILA Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.28
Previous CloseN/A
Volume208.69K
Average Volume (3M)592.89K
Market Cap
AU$37.09M
Enterprise ValueAU$30.24M
Total Cash (Recent Filing)AU$3.99M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Aug 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding247,235,090
10 Day Avg. Volume612,317
30 Day Avg. Volume592,891
Financial Highlights & Ratios
PEG Ratio-0.78
Price to Book (P/B)5.34
Price to Sales (P/S)0.00
P/FCF Ratio-11.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Island Pharmaceuticals Ltd News
PremiumCompany Announcements
Island Pharmaceuticals Director Increases Shareholding
PremiumCompany Announcements
Island Pharmaceuticals Announces Significant Development
PremiumCompany Announcements
Island Pharmaceuticals Announces Change in Substantial ShareholdingPremiumCompany Announcements
Island Pharmaceuticals Issues New Shares Following Option Exercise
PremiumCompany Announcements
Island Pharmaceuticals Lists New Securities on ASX
PremiumCompany Announcements
Island Pharmaceuticals’ Commitment to Combating Viral ThreatsOptions Prices
Currently, No data available
---
Ownership Overview
3.55% Insiders
―
Mutual Funds
― Other Institutional Investors
96.45% Public Companies and
Individual Investors
ILA FAQ
What was Island Pharmaceuticals Ltd’s price range in the past 12 months?
Island Pharmaceuticals Ltd lowest share price was AU$0.06 and its highest was AU$0.28 in the past 12 months.
What is Island Pharmaceuticals Ltd’s market cap?
Island Pharmaceuticals Ltd’s market cap is AU$37.09M.
When is Island Pharmaceuticals Ltd’s upcoming earnings report date?
Island Pharmaceuticals Ltd’s upcoming earnings report date is Aug 21, 2025 which is in 23 days.
How were Island Pharmaceuticals Ltd’s earnings last quarter?
Island Pharmaceuticals Ltd released its earnings results on Feb 27, 2025. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is Island Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Island Pharmaceuticals Ltd’s price is currently Overvalued.
Does Island Pharmaceuticals Ltd pay dividends?
Island Pharmaceuticals Ltd does not currently pay dividends.
What is Island Pharmaceuticals Ltd’s EPS estimate?
Island Pharmaceuticals Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Island Pharmaceuticals Ltd have?
Island Pharmaceuticals Ltd has 247,235,090 shares outstanding.
What happened to Island Pharmaceuticals Ltd’s price movement after its last earnings report?
Island Pharmaceuticals Ltd reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 14.286%.
Which hedge fund is a major shareholder of Island Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in AU:ILA
Island Pharmaceuticals Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ILA Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$21.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
120.58%
12-Months-Change
Fundamentals
Return on Equity
-143.22%
Trailing 12-Months
Asset Growth
144.04%
Trailing 12-Months
Company Description
Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd (ILA) is a biopharmaceutical company focused on developing and commercializing innovative therapies for the prevention and treatment of mosquito-borne viral diseases. The company's primary focus is on its lead product, ISLA-101, a drug aimed at preventing and treating dengue fever and other flavivirus infections. Island Pharmaceuticals leverages its expertise in viral disease research and drug development to address significant unmet medical needs in global health.
Technical Analysis
Actinogen Medical
―
Biotron
―
Immutep Ltd
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―